Author

E. Nadal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 2 Organism:C. elegans· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:behavioral assay· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. Villanueva· 4 shared C. Martinez-Fernandez· 2 shared D. Brena· 2 shared J. Ceron· 2 shared S. Honnen· 2 shared A. Alay· 1 shared A. Dawson· 1 shared A. Gonzalez-Suarez· 1 shared

Activity by Year

2017-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Villanueva

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Computer Modeling of Radiofrequency Cardiac Ablation including Heartbeat-Induced Electrode Displacement

J. J. Perez, A. Gonzalez-Suarez, E. Nadal, E. Berjano

This paper develops a dynamic computer model of radiofrequency cardiac ablation that simulates heartbeat-induced electrode displacement and compares lesion depth to experimental results.

bioRxiv · Dec 11, 2021Bioengineering

Insights into cisplatin-induced neurotoxicity and mitochondrial dysfunction in Caenorhabditis elegans

C. Martinez-Fernandez, M. Bergamino, D. Brena, N. Ventura, S. Honnen, A. Villanueva, E. Nadal, J. Ceron

This study investigates cisplatin-induced neurotoxicity and mitochondrial dysfunction in C. elegans using genetic, biochemical, and behavioral assays.

bioRxiv · Jun 3, 2021Cell Biology

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

E. Aliagas, A. Alay, M. Martinez-Iniesta, M. Hernandez-Madrigal, D. Cordero, M. Gausachs, E. Pros, M. Saigi, S. Busacca, A. Sharkley, A. Dawson, R. Palmero, S. Padrones, S. Aso, I. Escobar, , E. Nadal

This study evaluates CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma, finding they reduce tumor growth and improve survival by inducing cell cycle arrest and senescence.

bioRxiv · Feb 8, 2021 · PreprintCancer Biology

Multiple Low Dose therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

J. M. Fernandes Neto, E. Nadal, S. N. Ooft, E. Bosdriesz, L. Farre, C. McLean, S. Klarenbeek, A. Jurgens, H. Hagen, L. Wang, E. Felip, A. Martinez-Marti, E. Voest, L. Wessels, O. van Tellingen, , R. Bernards

This paper shows that using multiple low doses of drugs targeting different components of a signaling pathway can effectively treat EGFR inhibitor-resistant NSCLC without resistance development.

bioRxiv · Oct 29, 2019Cancer Biology

Genetic and cellular sensitivity of Caenorhabditis elegans to the chemotherapeutic agent cisplatin

F. J. Garcia-Rodriguez, C. Martinez-Fernandez, D. Brena, E. Nadal, M. Boxem, S. Honnen, A. Miranda-Vizuete, A. Villanueva, J. Ceron

This study investigates cisplatin sensitivity in C. elegans, identifying factors like DAF-16/FOXO, SKN-1/Nrf2, and the intrinsic apoptotic pathway, and discovers a resistance mechanism involving trxr-1 and selenocysteine.

bioRxiv · Dec 12, 2017Cancer Biology